Therapeutic Assessment of Diminazene Aceturate and Imidocarb Dipropionate against Bovine Babesiosis

The goal of the current study was to document the effectiveness of various antiparasitic medications in treating babesiosis in cattle from January 2023 and December 2024. Microscopic examination of stained blood smears revealed an overall prevalence of babesiosis was 21.87% (105/480), while the PCR, which targeted the 18s rRNA gene by creating an amplified product of 733 bp, revealed an overall prevalence of 38.54% (185/480). Thirty cattle with babesiosis were split into three groups and in each group ten cattle for the purpose of therapeutic evaluation. Cattle under Group 1 received injection of diminazene aceturate, under Group 2 received injection of imidocarb dipropionate, and under Group 3 received injections of both diminazene aceturate and imidocarb dipropionate in addition to comparable symptomatic and supportive therapy. On the first, third, seventh, and fourteenth days of treatment, post-therapeutic evaluations were conducted. When evaluating the clinical examination, hematological and biochemical analysis, no notable differences were observed in between the groups. However, a noteworthy distinction was observed in the decrease of parasitemia status both with-in the groups and in-between groups. Cattle under Group 3 which received both diminazene aceturate and imidocarb dipropionate, recovered earlier than cattle in other two groups which received single anti parasitic medication. Additionally, no recurrence was observed in cattle receiving combination therapy as opposed to those receiving either medication alone.